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Case ReportHigh-frequency oscillatory ventilation in RSV
bronchiolitis patients
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Utrecht, The NetherlandsIntroduction
Respiratory syncytial virus (RSV) is the leading cause of
bronchiolitis and pneumonia in infants and young children
(1–3). Prematurity, bronchopulmonary dysplasia (BPD),
congenital heart disease and immune disorders are well-
known risk factors associated with significant morbidity
and mortality (4–7). These children may need prolonged
hospitalization, mechanical ventilation and even extracor-
poreal membrane oxygenation (ECMO) when conventional
mechanical ventilation (CMV) fails (8–11).
RSV-induced respiratory failure is most often due to
obstructive lung disease, although acute respiratory distress
syndrome (ARDS) secondary to RSV infection has been
described (3).
High-frequency oscillatory ventilation (HFOV) may sig-
nificantly improve oxygenation and outcome in pre-term
infants with respiratory distress syndrome (12–16) and
beyond the neonatal period in patients with a variety of
diVuse alveolar diseases, such as ARDS and pneumonia
(17–21). However, in small airway disease HFOV is consid-
ered potentially hazardous because of the risk of air trap-
ping (17,22). Therefore, in clinical trials of HFOV, patients
with small airway disease, including bronchiolitis, are gen-
erally excluded from study (18). We have found only one
case report of HFOV to improve gas exchange and to avoid
ECMO in a bronchiolitis patient (23).
We report five patients with small airway disease caused
by RSV bronchiolitis who were treated with HFOV as a
rescue therapy after deterioration on CMV.Patients and MethodsPATIENTS
Between February 1994 and March 1997 we treated
five patients with severe bronchiolitis with HFOV. RSV0954-6111/99/060435+06 $12.00/0infection was confirmed using a positive immunofluorescent
antigen detection test on a nasal wash preparation. Patient
characteristics are presented in Table 1. Only patients with
RSV-induced obstructive small airway disease, as indicated
by hyperinflated lungs on chest X-ray (hyperlucidity and
depression of the diaphragm to below the 9th posterior rib),
were included in this report. RSV-pneumonia without
hyperinflation was not the subject of this study. All patients
had one or more risk factors for severe RSV infection:
preterm delivery in four patients; BPD in one patient; and
surgically corrected congenital heart disease in two patients.
Patient 3 had pre-existing BPD with nocturnal oxygen
requirement prior to admission. Patient 4 developed RSV-
bronchiolitis a few days after arterial switch procedure for
transposition of the great arteries. Her course was compli-
cated by bilateral pneumothoraces requiring chest tubes.
Patient 5 had bronchoscopically confirmed malacia of the
trachea extending into the left main bronchus.
All the patients were treated from admission onwards
with fluid restriction. If bacterial surinfection was sus-
pected, based on fever, purulent mucus, leucocytosis or
C-reactive protein (CRP) rise, antibiotics were started.
Ipratropiumbromide and salbutamol were tried but discon-
tinued because of no benefit. Corticosteroids were not
given.Received 15 September 1998 and accepted in revised form 22
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All patients were initially ventilated on a Servo 300
(Siemens-Elema, Solna, Sweden), either with pressure-
regulated volume control or with pressure control. Venti-
latory variables and corresponding blood-gas values just
prior to transition to HFOV are summarized in Table 2.
All patients were sedated with midazolam and paralysed
with vecuronium. Intravenous fluids and inotropes were
administered to maintain adequate haemodynamics. CMV
was changed to HFOV when one or both of the following
conditions were met: oxygenation index (OI) >13 in two
consecutive blood gas measurements over a 6-h period, or
peak inspiratory pressures >30 cm water despite the use of
permissive hypercapnia. The OI was calculated as mean
airway pressure (Paw) in cm H2O#FiO2#100/PaO2
"1 in
mmHg. Permissive hypercapnia was defined as an elevated? 1999 W. B. SAUNDERS COMPANY LTD
436 CASE REPORTSPaCO2 level with a pH >7·25 at a bicarbonate level of
20 mmol l"1.
All patients showed hypoxic respiratory failure except for
patient 2. Patient 5 showed both hypoxic and respiratory
failure.HIGH-FREQUENCY OSCILLATORY
VENTILATION
Informed consent from both parents was obtained prior to
the institution of HFOV. We used an electromagnetically
driven membrane oscillator (3100A, SensorMedics Critical
Care, Yorba Linda, CA, U.S.A.). Initial settings were:
mean airway pressure (Paw) 2–4 cm H2O above the Paw
on conventional ventilation; pressure amplitude (˜P)
adjusted to provide adequate chest wall movements; fre-
quency 10 Hz; inspiratory time 33%; bias gas flow 20 l
min"1; and FiO2 1·0. Paw was increased while reducing
FiO2 to 0·6, until percutaneous oxygen saturation was
¢90% and PaO2 ¢50 mmHg. Pressure amplitude was
adjusted to attain a pH ¢7·25 at a bicarbonate level
¢20 mmol l"1, irrespective of the PaCO2. Lung inflation
was monitored by repeated chest X-rays using the projec-
tion of the diaphragm against the posterior ribs as indi-
cator. Paw was not altered according to the degree of lung
inflation. General supportive care remained unchanged.Once the respiratory condition improved, the Paw was
decreased gradually in increments of 1 cm H2O as
oxygen saturation and arterial blood gases allowed. At
Paw <15 cm H2O, muscle relaxation was stopped,
patients were weaned directly to CPAP and extubated when
appropriate.Table 1. Patient characteristics
Patient Sex
Age
(months)
Weight
(g) Additional diagnosis
1 F 0·8 2600 Ex-prematurity (GA=36 weeks)
2 M 1·4 2740 Ex-prematurity (GA=33·5 weeks)
3 F 2·5 3500 Ex-prematurity (GA=28·5 weeks)
Bronchopulmonary dysplasia with supplemental
oxygen need before admission
4 F 1·5 3000 Surgically corrected TGA
5 M 3·7 4860 Ex-prematurity (GA=34 weeks)
Surgically corrected TAPVR
Tracheobronchomalacia
TGA, transposition of the great arteries; TAPVR, total abnormal pulmonary venous return; GA,
gestational age.Table 2. Conventional mechanical ventilation characteristics prior to transition to HFOV
Patient
PIP
(cm H2O)
PEEP
(cm H2O) FiO2
PaO2
(mmHg)
PaCO2
(mmHg) pH OI
1 32 7 0·6 39 38 7·52 26·2
2 38 2 0·5 71 54 7·24 11·5
3 34 5 1·0 58 47 7·34 25·8
4 28 10 0·6 58 47 7·38 18·6
5 38 6 0·6 60 84 7·18 16·6
PIP, peak inspiratory pressure; PEEP, positive end expiratory pressure; OI, oxygenation index.NITRIC OXIDE ADMINISTRATION DURING
HFOV
Patient 3 was additionally treated with nitric oxide (NO).
NO was administered by a ball valve flow meter into the
inspiratory limb of the HFO ventilatory circuit, 25 cm
proximal to the endotracheal tube. NO flow was calculated
according to the formula:
NO flow=[V*vent#(NO) del]/[(NO) tank"(NO) del],
where V*vent is the ventilator flow, (NO) del the required
NO concentration in parts per million (ppm) and (NO) tank
the NO concentration in ppm in the delivery tank. NO was
provided in tanks containing 800 ppm (Linde AG,
Düsseldorf, Germany). We have previously found this
method of NO administration during HFOV to be
accurate (24).
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HFOV AND GAS EXCHANGE
CHARACTERISTICS
HFOV characteristics are summarized in Table 3. The
mean duration of CMV prior to HFOV was 4·4 days (1–11
days); HFOV was continued for a mean duration of 12·2
days (7–21 days). The mean maximal ˜P used was 40 cm
H2O (range 35–50 cm H2O) and the mean maximal Paw
was 24 cm H2O (range 20–28 cm H2O). In patient 3, once
adequate oxygenation was achieved, attempts were made to
reduce the Paw because of haemodynamic impairment due
to extreme hyperinflation and because pulmonary inter-
stitial emphysema (PIE) appeared on chest X-ray (Fig. 1).
This resulted in severe hypoxaemia. In patient 4, ongoing
air leaks required replacement and regular repositioning of
the chest tubes during the first days on HFOV. After 3 days
Paw could be reduced without impairment of oxygenation
and air leaking ceased.
The progress of the OI during the first 48 h after initia-
tion of HFOV is shown in Fig. 2. After starting HFOV a
distinct decrease in OI was seen in patients 1, 2, 4 and 5.
Only in patient 3 was there an increase in OI during the first
48 h.NITRIC OXIDE INHALATION
In patient 3, NO was started 3 days after transition because
of clinical deterioration with haemodynamic instability, the
development of PIE and increasing OI (Figs. 1 and 2). NO
was administered at a concentration of 20 ppm. Within 6 h
there was a marked decrease in OI (Fig. 3) and Paw and
FiO2 could be reduced. NO administration was gradually
weaned and could be stopped after 14 days.COMPLICATIONS AND OUTCOME
During transition from CMV to HFOV, two patients
needed extra inotropic support and additional volume
supplement to maintain adequate haemodynamics. Despitemarked hyperinflation with appearance of pulmonary inter-
stitial emphysema, patient 3 did not develop pneumothorax
or pneumomediastinum. In patient 3, inadequate oxygen-
ation was countered by increasing Paw with a resultant
increase in lung volume with diaphragmatic levels below the
12th posterior rib. In the other patients adequate oxygen-
ation was achieved at comparable diaphragmatic levels to
those found during CMV (9th–10th posterior rib). Air leaks
in patient 4 were already present prior to HFOV and
resolved during HFOV.
All patients survived. Three patients required supplemen-
tary oxygen at discharge from the paediatric intensive care
unit. Only patient 3 required supplementary oxygen at day
30 after HFOV initiation. All patients were discharged
from hospital without supplementary oxygen and without
respiratory signs or symptoms.Table 3. HFOV characteristics
Patient
PICU
stay
(days)
CMV
duration
(days)
HFOV
duration
(days)
Maximum
Paw
(cm H2O)
Maximum
˜P
(cm H2O) Outcome
1 17 3 11 20 37 Survivor
Supplementary oxygen (<28 days)
2 21 11 7 20 40 Survivor
3 50 1 21 28 36 Survivor
Supplementary oxygen (>28 days)
4 14 6 12 24 35 Survivor
Supplementary oxygen (<28 days)
5 31 1 10 22 50 Survivor
PICU, paediatric intensive care unit.Discussion
High-frequency ventilation comprises a variety of venti-
latory techniques with the use of supraphysiological fre-
quencies as the single common denominator (25). DiVerent
equipment designs with diVerent characteristics, such as
inspiratory flow velocities and pressure waveforms, pro-
foundly aVect gas exchange and pulmonary mechanics and
therefore the incidence and nature of complications. In
high-frequency jet ventilation (HFJV) and high-frequency
flow interruption (HFFI), expiration is passive and depends
upon the time constants of the lung. HFJV and HFFI
always induce dynamic air trapping, the degree of which is
dependent on airway resistance and the compliance of the
respiratory system (26). In contrast, HFOV is characterized
by an active expiratory phase, which makes the occurrence
of dynamic air trapping considerably less (27). An increased
expiratory time, resulting in tracheal and alveolar mean
airway pressures below those at the tube inlet (28), further
decreases dynamic air trapping.
The mechanism of pulmonary overexpansion may be
diVerent during CMV from during HFOV. In CMV, as in
spontaneous breathing, true air trapping occurs with
438 CASE REPORTSFig. 1. Chest X-ray of patient 3 during HFOV with pulmonary overexpansion and the appearance of pulmonary
interstitial emphysema.inspiratory opening and expiratory closure of the inflamed
small airways. In HFOV, small airways are opened up and
kept open due to high mean airway pressures, engendering
a more equal ventilation throughout the lung. However, as
soon as the small airways are open, the high mean airway
pressure (over)distends the relatively normal compliant
alveoli. On the other hand, alveolar pressure swings during
HFOV are considerably less than during CMV (28), leading
to less shear stress on lung tissue.
Our patients all had dynamic air trapping during CMV,
as indicated by pulmonary overdistension on chest X-ray.
We did not include children with RSV-pneumonia without
overinflation as the use of HFOV in these patients is less
controversial. The use of relatively high mean airway
pressures in our patients during HFOV to achieve adequate
oxygenation did not induce a further increase in hyper-
inflation. Although it is our strategy to allow spontaneousbreathing in HFOV, we paralyse bronchiolitis patients to
prevent further air trapping.
Arnold et al. (18) have found an increasing OI at 24 and
48 h to be indicative of ultimate failure of HFOV and
recommend considering alternative treatments in such
cases. In bronchiolitis, the administration of NO might be
just such an alternative strategy to avoid ECMO (29), as in
our patient 3. A discussion of the use of inhaled NO, also a
weak bronchodilator, in improving oxygenation is beyond
the scope of this paper (30,31).
Our experience with HFOV in five bronchiolitis patients
does not support a conclusion that HFOV is superior to
CMV or other ventilatory techniques (9). However, con-
trary to current opinion, we have shown that small airway
disease may be successfully treated with HFOV. In spite of
severe overexpansion, all patients recovered without clini-
cally detectable pulmonary sequelae, shown by the absence
CASE REPORTS 439of respiratory signs and symptoms at discharge from the
hospital.
The ventilatory strategy of choice must be directed to
open up the small airways with high mean airway pressures,
to reduce pressure swings as far as possible by permissive
hypercapnia and to minimize dynamic air trapping both by
using longer expiratory than inspiratory times and by
avoiding spontaneous breathing.Acknowledgements
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Fig. 2. The oxygenation index (OI) of all patients prior
to and during the first 48 h on HFOV: t0 represents the
OI on CMV just prior to HFOV, t1 after stabilization
within 4 h on HFOV, and t2 and t3 after 24 and 48 h
on HFOV, respectively. ( , Patient 1; , patient 2;
+, patient 3; , patient 4; , patient 5.)40
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Fig. 3. The oxygenation index of patient 3 on HFOV
prior to and during the first 24 h on NO inhalation
therapy: t4 represents 1 h prior to NO inhalation therapy,
and t5, t6 and t7 represent 0·5 h, 5·5 h and 24 h after the
start of NO inhalation therapy, respectively.References
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